Your browser doesn't support javascript.
loading
Real world evidence of clinical predictors of glycaemic response to glucose-lowering drugs among Chinese with type 2 diabetes.
Wu, Hongjiang; Lau, Eric S H; Yang, Aimin; Fan, Baoqi; Ma, Ronald C W; Kong, Alice P S; Chow, Elaine; So, Wing-Yee; Chan, Juliana C N; Luk, Andrea O Y.
Afiliação
  • Wu H; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • Lau ESH; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • Yang A; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • Fan B; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, China.
  • Ma RCW; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • Kong APS; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • Chow E; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, China.
  • So WY; Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
  • Chan JCN; Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • Luk AOY; Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, China.
Diabetes Metab Res Rev ; 39(4): e3615, 2023 05.
Article em En | MEDLINE | ID: mdl-36652944
ABSTRACT

AIMS:

To examine whether simple clinical features can predict the 1-year glycaemic response to glucose-lowering drugs (GLDs) among Chinese with type 2 diabetes. MATERIALS AND

METHODS:

We used data from a diabetes risk assessment and complication screening programme and electronic medical records. We used linear regression models to examine the association between clinical features and 1-year glycaemic response to GLDs.

RESULTS:

Use of metformin (n = 15,433), sulphonylureas (SU) (n = 15,190), dipeptidyl peptidase-4 inhibitor (DPP-4i) (n = 7947), thiazolidinedione (TZD) (n = 4107), and sodium-glucose cotransporter 2 inhibitors (SGLT-2i) (n = 1883) were associated with a mean reduction of HbA1c ranging from 0.7% to 1.3% at one year. Men had a greater response to SU but a poorer response to metformin and TZD. Older age predicted a better response to all GLDs but not SGLT-2i, whereas increasing diabetes duration was associated with a poorer response to all GLDs except for DPP-4i. Obese patients responded greater to TZD and SGLT-2i but poorer to SU than those with normal weight. Patients with a higher level of triglycerides to high-density lipoprotein cholesterol ratio had a greater glycaemic response to TZD but a smaller response to SU and DPP-4i.

CONCLUSIONS:

Glycaemic response to GLDs differed considerably by clinical features among Chinese patients with type 2 diabetes.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores da Dipeptidil Peptidase IV / Metformina Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Diabetes Metab Res Rev Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Diabetes Mellitus Tipo 2 / Inibidores da Dipeptidil Peptidase IV / Metformina Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Diabetes Metab Res Rev Assunto da revista: ENDOCRINOLOGIA / METABOLISMO Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China